Artikel
Bevacizumab versus triamcinolone for treatment of diabetic macular edema in a pair-matched analysis
Suche in Medline nach
Autoren
-
Rainer Guthoff
- Würzburg/Germany
-
K. Hennemann
- Würzburg/Germany
-
W. Goebel
- Würzburg/Germany
-
W.F. Schrader
- Würzburg/Germany
| Veröffentlicht: | 18. Juni 2008 |
|---|
Gliederung
Text
Background: To retrospectively analyze the outcome of patients with diabetic macular edema (ME) treated by bevacizumab vs. triamcinolone.
Methods: 14 patients treated with bevacizumab for argon laser-refractory diabetic ME were matched pairwise with 5 TA treated patients in regard to initially comparable VA and central retinal thickness (CRT). VA and CRT, measured by OCT, at first and last presentation were evaluated. Previously vitrectomized eyes were not included.
Results: In the BVO group, mean initial VA (LogMAR) of bevacizumab patients (mean age 70±13 years) and TA patients (mean age 65±9 years) was 0.2±0.1 and 0.19±0.09, respectively. Initial CRT of bevacizumab patients and TA patients was 470±181 µm and 469±169 µm, respectively. Final VA of bevacizumab patients after 1.3 injection was 0.17±0.05, mean 0,2, at the end of a mean follow up of 8±3.8 months. Final VA of TA patients after a mean of 1.1 injections was 0.21±0.1, median 0,2, at the end of a mean follow up of 9.5±5.3 months. CRT decreased by 119±212µm, median 92µm, after bevacizumab und by 103±171µm, median 92µm, after TA.
Conclusions: This pair-machted analysis showed no significant long-term effect of both bevacizumab and TA on chronic diabetic macular edema after a single up to 3 injections.
